CA2584805C - Peptide anti-tumor agent - Google Patents

Peptide anti-tumor agent Download PDF

Info

Publication number
CA2584805C
CA2584805C CA2584805A CA2584805A CA2584805C CA 2584805 C CA2584805 C CA 2584805C CA 2584805 A CA2584805 A CA 2584805A CA 2584805 A CA2584805 A CA 2584805A CA 2584805 C CA2584805 C CA 2584805C
Authority
CA
Canada
Prior art keywords
peptide
isolated
purified
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2584805A
Other languages
English (en)
French (fr)
Other versions
CA2584805A1 (en
Inventor
Martin Jay Rosenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York University
Original Assignee
New York University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York University filed Critical New York University
Publication of CA2584805A1 publication Critical patent/CA2584805A1/en
Application granted granted Critical
Publication of CA2584805C publication Critical patent/CA2584805C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2584805A 2004-11-08 2005-11-04 Peptide anti-tumor agent Expired - Fee Related CA2584805C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62622004P 2004-11-08 2004-11-08
US60/626,220 2004-11-08
PCT/US2005/040078 WO2006052775A2 (en) 2004-11-08 2005-11-04 Peptide anti - tumor agent

Publications (2)

Publication Number Publication Date
CA2584805A1 CA2584805A1 (en) 2006-05-18
CA2584805C true CA2584805C (en) 2014-01-28

Family

ID=36337037

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2584805A Expired - Fee Related CA2584805C (en) 2004-11-08 2005-11-04 Peptide anti-tumor agent

Country Status (7)

Country Link
US (3) US7173110B2 (enExample)
EP (1) EP1812035B1 (enExample)
JP (2) JP5138378B2 (enExample)
AT (1) ATE484290T1 (enExample)
CA (1) CA2584805C (enExample)
DE (1) DE602005024161D1 (enExample)
WO (1) WO2006052775A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7173110B2 (en) * 2004-11-08 2007-02-06 New York University Peptide anti-tumor agent
WO2010120691A2 (en) * 2009-04-13 2010-10-21 Elc Management Llc Methionine sulfoxide peptide, compositions and methods of use
MX346043B (es) * 2012-01-06 2017-03-03 Novus Int Inc Tensioactivos basados en sulfoxido.
RU2620170C1 (ru) * 2016-08-02 2017-05-23 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России Применение катионных пептидов для индукции гибели клеток меланомы кожи человека
US10584306B2 (en) 2017-08-11 2020-03-10 Board Of Regents Of The University Of Oklahoma Surfactant microemulsions
EP3911662A4 (en) * 2019-01-14 2022-10-26 New York University CYCLIC PEPTIDE DIMERS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4307082A (en) 1979-07-10 1981-12-22 New York University Method for the extraction of a factor that mediates contact inhibition of cell growth
US4530784A (en) 1983-08-19 1985-07-23 New York University Large scale extraction process for contact inhibitory factor
DE3841763A1 (de) * 1988-12-12 1990-06-13 Basf Ag Neue tnf-peptide
US5942492A (en) * 1996-11-12 1999-08-24 Angstrom Pharmaceuticals, Inc. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
US20050124531A1 (en) * 2002-02-22 2005-06-09 New York University Biological inhibitions induced by contact inhibitory factor
JP2004083427A (ja) * 2002-08-23 2004-03-18 Microbial Chem Res Found 環状ヘキサペプチド及びプロテアソーム阻害剤
US7173110B2 (en) * 2004-11-08 2007-02-06 New York University Peptide anti-tumor agent

Also Published As

Publication number Publication date
US7173110B2 (en) 2007-02-06
JP2013005804A (ja) 2013-01-10
US20070123454A1 (en) 2007-05-31
EP1812035A2 (en) 2007-08-01
WO2006052775A3 (en) 2006-07-20
JP2008518622A (ja) 2008-06-05
CA2584805A1 (en) 2006-05-18
EP1812035A4 (en) 2008-04-16
WO2006052775A2 (en) 2006-05-18
US20060258573A1 (en) 2006-11-16
EP1812035B1 (en) 2010-10-13
US8003598B2 (en) 2011-08-23
JP5138378B2 (ja) 2013-02-06
US7691964B2 (en) 2010-04-06
ATE484290T1 (de) 2010-10-15
DE602005024161D1 (de) 2010-11-25
US20100305044A1 (en) 2010-12-02

Similar Documents

Publication Publication Date Title
AU2019218786B2 (en) Cell-permeable stapled peptide modules for cellular delivery
CA2368431C (en) Melanocortin receptor ligands
US8003598B2 (en) Peptide anti-tumor agent
EP3724216A1 (en) Stabilized peptide-mediated targeted protein degradation
US20100292164A1 (en) Dimerized peptide
GB2346616A (en) Delivery vectors comprising truncated and modified forms of penetratin
ES2375038T3 (es) Derivados de metastina y su uso.
CA2489227A1 (en) Hla-a24-restricted cancer antigen peptides
US20230414702A1 (en) Compounds and pharmaceutical use thereof in the treatment of cancer
RS50857B (sr) Konjugati polimera neublastina i postupci za njihovu upotrebu
AU2020409569B2 (en) Retro-inverso peptides
JP2020127419A (ja) 新規なカリウムチャネルブロッカー及び自己免疫疾患の治療におけるそれらの使用
CZ20011700A3 (cs) Benzoxazolové deriváty a léčiva na jejich bázi
CN107108756A (zh) 细胞穿透性肽
US20210395311A1 (en) Cyclic peptide dimers
CN116693622A (zh) 基于Ascaphin的芳香硫醚订书肽类抗肿瘤活性化合物、制备方法及应用
US9334314B2 (en) Peptide compounds derived from melanotransferrin and uses thereof
CN115160406A (zh) 一类新型抗肿瘤环肽活性分子的制备方法与应用
KR102077984B1 (ko) 피부 주름 예방 및 개선용 조성물
HK40054557A (en) Retro-inverso peptides
HK1081975B (en) Dimerized peptide

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20161104